Table 1.
Participant characteristics
| Variable | Population value |
|---|---|
| Age, years, mean (SD) | 65.3 (9.5) |
| Female, n (%) | 106 (44) |
| eGFR, ml/min/1.73m2, mean (SD) | 67 (25) |
| Weight, Kg, mean (SD) | 89.0 (20.1) |
| BMI, kg/m2, mean (SD) | 31.0 (6.4) |
| Hypertension, n (%) | 157 (65) |
| SBP, mmHg, mean (SD) | 136 (22) |
| DBP, mmHg, mean (SD) | 81 (13) |
| MABP (1/3 SBP + 2/3 DBP), mmHg, mean (SD) | 99 (13) |
| HbA1c mean, mmol/mol, (SD) | 53 (18) |
| Total Cholesterol, mean, mmol/L (SD) | 3.92 (1.18) |
| HDL, mean, mmol/L (SD) | 1.33 (0.45) |
| LDL, mean, mmol/L (SD) | 2.28 (0.97) |
| Troponin, mean, mmol/L (SD) | 17.8 (28.9) |
| CRP, mean, mmol/L (SD) | 9.5 (35.6) |
| Pack Years, mean (SD) | 39.8 (35.0) |
| CVD, n (%) | 100 (41.5) |
| Diabetes mellitus, n (%) | 93 (39) |
| Type 1, n (%) | 13 (5) |
| Type 2, n (%) | 80 (33) |
| Insulin, n (%) | 29 (31) |
| Previous CVA, n (%) | 19 (8) |
| Antihypertensives, n (%) | 83 (35) |
| Hypoglycaemics, n (%) | 68 (29) |
| Statins, n (%) | 164 (69) |
| Diuretics, n (%) | 63 (27) |
| NSAIDs, n (%) | 12 (5) |
| Vitamin supplements, n (%) | 48 (20) |
| Rheumatoid arthritis, n (%) | 10 (9) |
| Hypertension treatment, n (%) | |
| None | 78 (33) |
| < 5 years | 54 (23) |
| 5–10 years | 38 (16) |
| > 10 years | 64 (27) |
| Smoking, n (%) | |
| Never | 119 (49) |
| Ex | 87 (36) |
| Current | 35 (15) |
| Alcohol, n (%) | |
| none | 134 (56) |
| 1–5 units | 38 (16) |
| 6–10 units | 28 (12) |
| 15–20 units | 25 (10) |
| > 25 units | 12 (5) |
| QRISK2 score, n (%) | |
| 1 | 38 (34) |
| 2 | 35 (31) |
| 3 | 38 (34) |
SD Standard deviation, eGFR estimated glomerular filtration rate, SBP Systolic blood pressure, DBP Diastolic blood pressure, MABP Mean arterial blood pressure, HbA1c Glycated haemoglobin A1c, HDL High density lipoprotein, LDL Low density lipoprotein, CRP C reactive protein, CVD Cardiovascular disease, CVA Cerebrovascular accident, NSAIDs Non-steroidal anti-inflammatory drugs